Advances in clinical studies of hydroxyethyl starch

Chinese Pharmaceutical Journal

Volumn 42, Issue 9, 2007, Pages 646-649

  Zhou, Xin ^a   Zhang, Xiao Le ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH;

ARTICLE; MEDICAL LITERATURE; MEDICAL RESEARCH;

EID: 54549127308     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. WU Z H. Modern concept of fluid replacement in the surgical patients[J]. J Surg Concept Pract,2004,9(4):343-344.
2. BARON J F. Crystalloids versus colloids in the treatment of hypovolemic shock[A]. In: Vincent J L, ed. Yearbook of Intensive Care and Emergency Medicine[M]. Berlin: Springer,2000:443-466.
3. TREIB J, HAASS A, PINDUR G, et al. All medium starches are not the same: influence of the de- gree of hydroxyethyl subst: tution of hydroryetbyl starch on plasma volume, hemorrheolog- ic conditions, and coagulation[J]. Transfu,1996,36(5):450-455.
4. TREIB J, HAASS A, PINDUR G, et al. Influence of the C2/C6 hydroxyethylation ratio of hydro- xyethyl starch (HES) on hemorheology, coagulation and elimination kinetics[J]. Thromb Haemost,1995,74(6):1452- 1456.
5. LAXENAIRE M C, CHARPENTIER C, FELDMAN L. Anaphylactoid reactions to colloid plasma substitutes: Incidence, risk factors mechanisms. A French multicenter prospective study[J]. Ann Fr Anesth Reanim,1994,13(3):301- 310.
6. BOLDT J, LEHMANN A, ROMPERT R, et al. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardio pulmonary bypass[J]. J Cardiothorac Vasc Anesth,2000,14(3):264-268.
7. DEHNE M G, MUHLING J, SABLOTZKI A, et al. Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment[J]. J Clin Anesth,2001,13(2):103-111.
8. YEH T J, PARMAR J M, REBEYKA I M, et al. Limiting edema in neonatal cardio pulmonary by pass with narrow range molecular weight hydroxyethyl starch[J]. J Thorac Cardiovasc Surg,1992,104(3):659-665.
9. WISSELINK W, PATETSIOS P, PANETTA T F, et al. Medium molecular weight pentastarch reduces reperfusion injury by decreasing capillary leak in ananimal model of spinal cord ischemia[J]. J Vasc Surg,1998,27(1):109- 116.
10. CHIANG C H, WU C P, PERNG W C, et al. Dexamethasone and pentastarch produce additive attenuation of ischaemia/reperfusion lung injury[J]. Clin Sci,2000,99(5):413-419.
11. ALLISON K P, GOSLING P, JONES S, et al. Randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation[J]. J Trauma,1999,47(6):1114-1121.
12. FERRARA J J, DYESS D L, COLLINS J N, et al. Effects of pentafraction administration on microvascular permeability alterations induced by graded thermal injury[J]. Surg,1994,115(2):182-189.
13. ELLGER B, FREYHOFF J, VOGT M, et al. High dose volume replacement using HES130/0.4 during major surgery does not alter coagulation[J]. Eur J Anesth,2002,19(24):77.
14. JUNGHEINRICH C. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopae- dic surgery: a randomized, double-blind study[J]. Drugs R & D,2004,5(1):1-9.
15. HAISCH G. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES130/0.4) on coagulation in patients undergoing major abdominal surg-ery[J]. Anesth Analg,2001,92(3):565-571.
16. WOESSNER R. Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl st- arch 130/0.4 or crystalloid solution on hemodynamics, rheology and homeostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study[J]. Pathophysiol Haemost Thromb,2003,33(3):121-126.
17. BOLDT J. Influence of two different volume replacement regimens on renal function in elder- ly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin[J]. Intensive Care Med,2003,29(5):763- 769.
18. JUNGHEINRICH C, SCHARF R, WARGENAU M, et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6% 500 mL) in mild-to severe renal impairment[J]. Anesth Analg,2002,95:544-551.
19. NEFF T A, JUNGHEINRICH C, DOELBERG M, et al. Advantages of 6% hydroxyethyl starch 130/0.4 (Voluven) at repetitive high dose levels in patients with severe craniocerebral trauma[J]. Critical Care,2001,5(11):114-116.
20. KASPER S M, MEINERT P, KAMPE S, et al. Large-dose hydroxyethyl starch 130/0.4 dose not in- crease blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended dose[J]. Anesth,2003,99:4247.
21. PENG C H, WU W X. Diagnosis, treatment and prevention of SIRS caused by biliary surgery emergency[J]. Chin J Practical Surg,2003,23(6):329-331.
22. LANG K, SUTTNER S, BOLDT J, et al. Volume replacement with HES130/0.4 may reduce the inflammatory response in patients under going major abdominal surgery[J]. Can J Anaesth,2003,50(10):1009-1016.
23. BOLDT J, DUCKE M, KUMLE B, et al. Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery[J]. Intensive Care Med,2004,30(3): 416-422.
24. LOCHBÜHLER H, GALU C, HAGEMANN H. Hydroxyethyl starch HES130/0.4 in paediatric surge- ry: results of an explorative, controlled, multicentre safety study[J]. Critical Care,2003,7(2):107-111.
25. BOLDT J. Human albumin on the intensive care unit: Can we live without it[A]. In: Vincent J L, ed. Yearbook of Intensive care and Emergency Medicine[M]. Berlin: Springer,2000:467-475.
26. COCHRANE INJURIES GROUP ALBUMIN REVIEWERS. Human albumin administration in critically ill patients: systematic review of randomized controlled trials[J]. Br Med J,1998,317(7153):235-240.